Zoran Zdraveski
General Counsel at TSCAN THERAPEUTICS, INC.
Net worth: 2 M $ as of 31/05/2024
Zoran Zdraveski active positions
| Companies | Position | Start | End |
|---|---|---|---|
| TSCAN THERAPEUTICS, INC. | General Counsel | 09/09/2021 | - |
| Corporate Secretary | 09/09/2021 | - |
Career history of Zoran Zdraveski
Former positions of Zoran Zdraveski
| Companies | Position | Start | End |
|---|---|---|---|
| MAGENTA THERAPEUTICS | General Counsel | 01/04/2017 | 01/04/2021 |
| Corporate Secretary | 01/03/2018 | 01/04/2021 | |
| EPIZYME, INC. | Corporate Officer/Principal | 01/07/2012 | 01/04/2017 |
Training of Zoran Zdraveski
| Massachusetts Institute of Technology | Doctorate Degree |
| Suffolk University Law School | Graduate Degree |
| Southern Methodist University | Undergraduate Degree |
Statistics
International
| United States | 7 |
Operational
| General Counsel | 2 |
| Corporate Secretary | 2 |
| Corporate Officer/Principal | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| TSCAN THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Zoran Zdraveski
- Experience
